Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

A bispecific antibody (BsAb) targeting the epidermal growth factor receptor (EGFR) and mesenchymal–epithelial transition factor (MET) pathways represents a novel approach to overcome resistance to targeted therapies in patients with non–small cell lung cancer. In this study, we sequentially screened...

Descripción completa

Detalles Bibliográficos
Autores principales: Neijssen, Joost, Cardoso, Rosa M.F., Chevalier, Kristen M., Wiegman, Luus, Valerius, Thomas, Anderson, G. Mark, Moores, Sheri L., Schuurman, Janine, Parren, Paul W.H.I., Strohl, William R., Chiu, Mark L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113745/
https://www.ncbi.nlm.nih.gov/pubmed/33839159
http://dx.doi.org/10.1016/j.jbc.2021.100641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113745/
https://www.ncbi.nlm.nih.gov/pubmed/33839159
http://dx.doi.org/10.1016/j.jbc.2021.100641

Ejemplares similares